Total Holdings
130
As of Oct 4, 2026
Virtus Biotech Clinical Trials ETF
BBCNYSEARCAVirtus Investment PartnersEquity
$39.12Today:- (-)1Y +36.71%
As of Oct 16, 2026 close
- Assets (AUM)
- $42.32M
- Expense ratio
- 0.65%
- Dividend yield
- 1.59%
- Holdings
- 130
- 52-week range
- $28.73$56.18
- Volume (live)
- -
- Avg. volume (3M)
- 22.28K
BBC ETF Holdings: Virtus Biotech Clinical Trials ETF
Every listed position with its portfolio weight, plus sector breakdown and geographic exposure for this Equity ETF. Analyze fund diversification and concentration.
Top 10 Holdings
14.5%
Share of fund assets
Assets (AUM)
$42.32M
Total fund assets
Expense Ratio
0.65%
Annual management fee
Portfolio Allocations
Distribution breakdown by sector, asset type, and geographic region. Understand the fund's diversification strategy across markets and asset classes.
Loading chart...
Top 54 of 130 BBC Holdings by Portfolio Weight
Holdings as of Oct 4, 2026. Ticker, name, asset type and portfolio weight for each position. Fund disclosures available to us list the largest 54 positions.
Scroll to see more
| # | Symbol | Name | Type | Weight |
|---|---|---|---|---|
| 1 |  | Kodiak Sciences Inc. | Stock | 2.08% |
| 2 |  | AbCellera Biologics Inc. | Stock | 1.97% |
| 3 |  | Amylyx Pharmaceuticals Inc. Common Stock | Stock | 1.59% |
| 4 |  | Xencor, Inc. | Stock | 1.51% |
| 5 |  | First Tracks Biotherapeutics | Stock | 1.47% |
| 6 |  | MBX Biosciences, Inc. | Stock | 1.23% |
| 7 |  | Sellas Life Sciences Group Inc | Stock | 1.19% |
| 8 |  | 4D Molecular Therapeutics, Inc. | Stock | 1.16% |
| 9 |  | ATAI Life Sciences BV | Stock | 1.13% |
| 10 |  | Definium Therapeutics, Inc. | Stock | 1.13% |
| 11 |  | ORIC Pharmaceuticals, Inc. | Stock | 1.11% |
| 12 |  | Adlai Nortye Group Ltd. | Stock | 1.10% |
| 13 |  | Replimune Group, Inc. | Stock | 1.10% |
| 14 |  | Monopar Therapeutics Inc | Stock | 1.08% |
| 15 |  | Zenas BioPharma, Inc. | Stock | 1.07% |
| 16 |  | uniQure N.V | Stock | 1.05% |
| 17 |  | Nurix Therapeutics, Inc. | Stock | 1.02% |
| 18 |  | Revolution Medicines, Inc. | Stock | 1.01% |
| 19 |  | SpyGlass Pharma, Inc. | Stock | 1.01% |
| 20 |  | LB Pharmaceuticals Inc Common Stock | Stock | 1.01% |
| 21 |  | Recursion Pharmaceuticals, Inc. | Stock | 0.98% |
| 22 |  | Achieve Life Sciences, Inc. | Stock | 0.98% |
| 23 |  | Vor Biopharma Inc. | Stock | 0.98% |
| 24 |  | Immix Biopharma Inc | Stock | 0.97% |
| 25 |  | IDEAYA Biosciences, Inc. | Stock | 0.97% |
| 26 |  | Vir Biotechnology, Inc. | Stock | 0.97% |
| 27 |  | REGENXBIO Inc | Stock | 0.97% |
| 28 |  | Relay Therapeutics, Inc. | Stock | 0.96% |
| 29 |  | ANRO | Stock | 0.96% |
| 30 |  | Cullinan Management, Inc | Stock | 0.95% |
| 31 |  | Janux Therapeutics, Inc. | Stock | 0.94% |
| 32 |  | Immunome, Inc | Stock | 0.93% |
| 33 |  | Oruka Therapeutics, Inc. | Stock | 0.93% |
| 34 |  | Candel Therapeutics Inc | Stock | 0.92% |
| 35 |  | Apogee Therapeutics, Inc. Common Stock | Stock | 0.92% |
| 36 | ELYM | Eliem Therapeutics Inc | Stock | 0.91% |
| 37 |  | Assembly Biosciences, Inc | Stock | 0.90% |
| 38 |  | MeiraGTx Holdings plc | Stock | 0.90% |
| 39 |  | Viridian Therapeutics Inc | Stock | 0.89% |
| 40 |  | DMRA | Stock | 0.89% |
| 41 |  | Sana Biotechnology, Inc | Stock | 0.88% |
| 42 |  | Dyne Therapeutics Inc | Stock | 0.86% |
| 43 |  | Praxis Precision Medicines, Inc | Stock | 0.85% |
| 44 |  | JBIO | Stock | 0.84% |
| 45 |  | Kymera Therapeutics, Inc | Stock | 0.83% |
| 46 |  | Design Therapeutics, Inc. Common Stock | Stock | 0.82% |
| 47 |  | Dianthus Therapeutics Inc. | Stock | 0.81% |
| 48 |  | Avalo Therapeutics Inc | Stock | 0.81% |
| 49 |  | GH Research PLC | Stock | 0.81% |
| 50 |  | CG Oncology, Inc. Common stock | Stock | 0.81% |
| 51 |  | Neurogene Inc | Stock | 0.80% |
| 52 |  | Immunovant Inc | Stock | 0.79% |
| 53 |  | Vaxcyte, Inc | Stock | 0.79% |
| 54 |  | Spyre Therapeutics Inc. | Stock | 0.79% |
Source: Fund holdings disclosures. Data as of Oct 4, 2026. Data sources and methodology
Frequently Asked Questions About Virtus Biotech Clinical Trials ETF Holdings
What are the top holdings in BBC?
As of Oct 4, 2026, Virtus Biotech Clinical Trials ETF (BBC) holds 130 securities. The largest are Kodiak Sciences Inc. (2.08%), AbCellera Biologics Inc. (1.97%), Amylyx Pharmaceuticals Inc. Common Stock (1.59%). The holdings table lists each position by portfolio weight with its ticker, name and asset type.
How concentrated is BBC's portfolio?
As of Oct 4, 2026, the 10 largest positions make up 14.5% of BBC's assets. A concentrated portfolio has fewer large positions with higher individual weights, while a diversified portfolio distributes holdings more evenly.
What is BBC's sector allocation?
The Sector Allocation chart shows how BBC distributes investments across different industries like Technology, Healthcare, Financials, and more. This sector exposure helps understand the fund's industry diversification strategy.
What countries does BBC invest in?
BBC's geographic exposure is shown in the Countries tab under Portfolio Allocations. This reveals the fund's international diversification and exposure to different regions and global markets.
How diversified is BBC ETF?
BBC's diversification can be assessed by reviewing its 130 holdings (as of Oct 4, 2026), sector allocation, and geographic exposure. A well-diversified ETF spreads investments across multiple securities, sectors, and regions to reduce concentration risk.